|
1）Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012; 18: 375-7
|
|
|
|
2）Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18: 378-1
|
|
|
|
|
|
3）Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012; 18: 382-4
|
|
|
|
|
|
4）Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012; 22: 436-45
|
|
|
|
|
|
5）Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013; 3: 630-5
|
|
|
|
|
|
6）Li F, Feng Y, Fang R, et al. Identification of RET gene fusion by exon array analyses in “pan-negative” lung cancer from never smokers. Cell Res. 2012; 22: 928-31
|
|
|
|
|
|
7）Yokota K, Sasaki H, Okuda K, et al. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. Oncol Rep. 2012; 28: 1187-92
|
|
|
|
|
|
8）Suehara Y, Arcila M, Wang L, et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res. 2012; 18: 6599-608
|
|
|
|
|
|
9）Matsumoto S, et al. A new nationwide genomic screening system in Japan for the development of targeted therapies against advanced non-small cell lung cancers with rare driver mutations. J Clin Oncol. 2014; 32: 5s（suppl; abstr 11007）
|
|
|
|
|